-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of August 17, the State Administration of Health Care Administration announced the Work Programme for the Adjustment of the National Health Insurance Drug Catalog 2020 and the Guidelines for the Adjustment and Declaration of the National Health Insurance Drug Catalog for 2020.
the time frame for admission to the new version of Medicare will be adjusted from December 31, 2019 to August 17, 2020.
also means that innovative drug products and adaptives approved in 2020 will have access to health insurance.
, according to the 2020 National Health Insurance Drug Catalog Adjustment Work Programme, seven new drugs could be included in the 2020 drug catalog.
These seven specifics include: drugs for the treatment of respiratory diseases associated with neo-corona pneumonia, drugs included in the National Essential Medicines List (2018 edition), inclusion in the list of new drugs in clinically urgent need abroad, encouragement of generic drugs or encouragement of research and development to declare lists of children's medicines drugs approved for market by the State Drug Administration before August 17, 2020 (inclusive, the same as between 2020); During the 7th period, the new generic name drug approved for listing by the State Drug Administration, and from January 1st, 2015 to August 17th, 2020, according to the results of clinical trials, the state drug regulatory department to apply for additional applications and obtain approval, adaptation, functional treatment, etc. occurred significant Changed drugs; by December 31, 2019, the main active ingredients of five or more new provincial-level basic medical insurance drugs catalogues were included in the first batch of national key monitoring and rational drug use drugs catalogues (chemicals and biological products).
the scope of the new version of the drug catalog includes three: drugs that have been revoked, revoked or cancelled by the State Drug Administration, and drugs that have been assessed to be more risky than beneficial, taking into account such factors as clinical value, adverse reactions and drug economy.
in the industry, one of the highlights of the health-care catalog adjustment is that new drugs will accelerate their entry into the health-care catalog.
It is understood that because of the high price of new drugs, it was difficult to have access to health insurance, and now new drugs will get tickets, or more domestic innovative drugs to speed up into health insurance, conducive to its domestic market to obtain a level playing field, effectively achieve import substitution, and will not bring pressure on health insurance funds to pay.
approved new drugs into health insurance is also the drug companies, patients look forward to.
, for example, Baiji Shenzhou said the company will speed up docking and communication with the health care sector to help new drugs get into health care more quickly.
it is learned that Baiji Shenzhou BTK inhibitor product Zebutini was approved for listing in June this year, this is the first time completely developed by domestic pharmaceutical companies, the FDA approved the listing of new anti-cancer drugs.
Compared with the price of similar foreign products, Zebtinib's treatment costs have been significantly reduced by half, and commercial insurance reimbursements are available, and insurance companies will pay a percentage of the cost of the drug to reduce the financial burden on patients.
if the product successfully enters the new version of health insurance, for patients, will further reduce the burden of drug costs.
, of course, new drugs into health insurance, price cuts are also a concern of the market.
The new version of the health insurance catalogue adjustment programme defines the scope for adjusting the payment criteria for medicines, including negotiated medicines that are within the validity period of the agreement and that the payment criteria need to be redefined in accordance with the agreement;
, there is some room for price reduction for such drugs in the range.
.